Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial

Recruiting now · Not applicable

Conditions studied: Heart Failure, Ejection Fraction, Recovery of Function

In brief

Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.

Key facts

Study ID

NCT06724653

Run by

Chungnam National University Hospital

People needed

150

Starts

2025-03-06

Expected to finish

2027-11-26

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• initial echocardiogram ejection fraction less than 40%
• follow up echocardiogram ejection fraction over 50% and LVEDD index normal range
• NTprobnp criteria
• eGFR ≥60 ; less 440
• eGFR 45-59: less 980
• eGFR 30-44; less 1220
• eGFR < 30 : less 5300
• in HD; no criteria for NTproBNP
• on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)

You may not qualify if…

• under age 18 year
• uncontrolled BP ( over 150/90)
• coronary revascularization within 6 months
• significant valve disease
• arrhythmia requiring rate control
• CKD with albuminuria ( over 30mg/g)
• Pregnancy

Where it is running

• Jeonbuk national university hospital — Jeonju, Jeollabuk-do, South Korea (enrolling)
• Chungnam national university hospital — Daejeon, Republic of Korea, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.